Long-term safety of HSK39004 inhaled medicine for COPD
Part of Lungs & breathing clinical trials.
This study tests whether a new inhaled medication called HSK39004 is safe and effective for people with moderate to severe COPD (a lung disease that makes breathing difficult). You would use this medicine regularly over a long period and have your lung function and symptoms checked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–80 years old
- Diagnosed with COPD with specific lung function test results (FEV1 between 30% and 80% of predicted)
- Moderate or worse shortness of breath (mMRC score of 2 or higher)
- No active respiratory infection in the past 6 weeks
- No severe heart disease, recent heart attack, or uncontrolled high blood pressure
- No history of lung surgery in the past 12 months, and not currently requiring oxygen therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.
This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests a new dry powder inhaler (HSK39004) for long-term safety in people with moderate to severe COPD. It may help if your breathing is limited despite current treatment.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.